Spyglass Pharma (NASDAQ:SGP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Spyglass Pharma (NASDAQ:SGP) to a hold rating in a research report sent to investors on Tuesday.

Spyglass Pharma Trading Up 4.1%

SGP stock opened at $29.68 on Tuesday. Spyglass Pharma has a one year low of $20.16 and a one year high of $32.44.

Insider Buying and Selling at Spyglass Pharma

In related news, Director Ra Capital Management, L.P. bought 3,690,000 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $59,040,000.00. Following the purchase, the director directly owned 5,966,439 shares of the company’s stock, valued at approximately $95,463,024. This trade represents a 162.10% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

About Spyglass Pharma

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).